Parschauer Karah Herdman sold $47K of RARE
Parschauer Karah Herdman (EVP and Chief Legal Officer) sold 1,899 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $24.62 on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the officer’s sale details (shares, price, post-transaction holdings) under a pre-arranged 10b5-1 plan; no new company fundamentals are disclosed.
Market read
Traders may log the insider sale as a data point, but it is not a catalyst for repricing absent other news.
What to watch
The filing does not state motives; without context on prior insider activity frequency/size, interpreting it as bearish is speculative.
Background
The article is an SEC Form 4 insider transaction disclosure (open-market sale) for Ultragenyx Pharmaceutical Inc.
Ticker impact
Ultragenyx (RARE) disclosed an EVP/Chief Legal Officer open-market sale of 1,899 shares at $24.62 on a 10b5-1 plan.
Low near-term impact; any reaction is likely noise unless paired with other company-specific news.
Form 4 shows a small, pre-planned open-market sale by an officer; the filing provides no new operational, clinical, or regulatory information.
Market effects
Minimal—single insider transaction without accompanying biotech catalyst does not materially change sector risk.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated or unusually timed sales can coincide with internal risk perceptions; traders may watch for follow-on filings.
Key entities
- issuerUltragenyx Pharmaceutical Inc.
RARE, subject of the Form 4 insider transaction disclosure.
- insiderParschauer Karah Herdman
EVP and Chief Legal Officer who sold 1,899 shares via an open-market sale under a 10b5-1 plan.